Heart failure (HF) is associated with a high morbidity and mortality burden. In light of more
recent evidence, SGLT2 inhibitors are currently recommended as first-line therapy in …

Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been studied in
patients with heart failure, type 2 diabetes, chronic kidney disease, atherosclerotic …

Background Anthracycline-mediated adverse cardiovascular events are among the leading
causes of morbidity and mortality in patients with cancer. Sodium-glucose cotransporter 2 …

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction:
post-hoc analyses of the Page 1 Ertugliflozin and hospitalization for heart failure across the …

Aims Recurrent heart failure hospitalization (HFH) is an important feature of the progression
of heart failure (HF). In the Treatment of Preserved Cardiac Function Heart Failure with an …

Conclusions WHF is an emerging entity within HF that defines itself as a unique point of
interest. Understanding it as a clinical measure of where a patient's HF is evolving allows for …

As the prevalence of older adults with inflammatory bowel disease (IBD) is rising,
understanding the unique challenges in both diagnosis and management is becoming …

Heart failure (HF) is a complex, life-threatening condition characterized by high mortality,
morbidity, and poor quality of life. Despite studies of epidemiology, pathogenesis, and …

Introduction Type 2 diabetes (T2D) is associated with severe complications, including
chronic kidney disease (CKD), cardiovascular disease, heart failure and premature death …

2022). Our weekly content of original research, review articles, and opinion pieces covered
the breadth of cardiology. The continuous flow of manuscripts submitted to our journal for the …